<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01332019</url>
  </required_header>
  <id_info>
    <org_study_id>105MS302</org_study_id>
    <secondary_id>2010-024477-39</secondary_id>
    <nct_id>NCT01332019</nct_id>
  </id_info>
  <brief_title>Long-Term Safety and Efficacy Study of Peginterferon Beta-1a</brief_title>
  <acronym>ATTAIN</acronym>
  <official_title>A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the long-term safety and tolerability of
      peginterferon beta-1a (BIIB017) in participants originally treated in Study 105MS301
      (NCT00906399) who continue peginterferon beta-1a treatment. The secondary objective of this
      study is to describe long-term multiple sclerosis (MS) outcomes in participants originally
      treated in Study 105MS301 (NCT00906399) who continue peginterferon beta-1a treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing Adverse Events (AEs) Serious AEs, and Discontinuations Due to AEs</measure>
    <time_frame>up to 4 years</time_frame>
    <description>AE: any untoward medical occurrence that did not necessarily have a causal relationship with study treatment. SAE: any untoward medical occurrence that at any dose: resulted in death; in the view of the Investigator, placed the participant at immediate risk of death (a life threatening event); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect; any other medically important event that, in the opinion of the Investigator, could have jeopardized the participant or may have required intervention to prevent one of the other outcomes listed in the definition above. Data collected after Amendment 3 took effect were excluded for participants enrolled into study 105MS302 on every 4 week dosing, but not excluded for participants enrolled on every 2 week dosing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Potentially Clinically Significant Hematology Laboratory Abnormalities</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Data collected after Amendment 3 took effect were excluded for participants enrolled into study 105MS302 on every 4 week dosing, but not excluded for participants enrolled on every 2 week dosing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Shifts From Baseline: Liver Function Laboratory Values</measure>
    <time_frame>Baseline (BIIB017 Treatment Baseline from Study 105MS301) up to 4 years</time_frame>
    <description>Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high. For participants who switched to alternative MS medications, data after switch and 14 days after last dose of study treatment are excluded. Data collected after Amendment 3 took effect were excluded for participants enrolled into study 105MS302 on every 4 week dosing, but not excluded for participants enrolled on every 2 week dosing. ALT=alanine aminotransferase; AST=aspartate aminotransferase; GGT=gamma-glutamyl transferase.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Shifts From Baseline: Kidney Function and Other Blood Chemistry</measure>
    <time_frame>Baseline (BIIB017 Treatment Baseline from Study 105MS301) up to 4 years</time_frame>
    <description>Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high. For participants who switched to alternative MS medications, data after switch and 14 days after last dose of study treatment are excluded. Data collected after Amendment 3 took effect were excluded for participants enrolled into study 105MS302 on every 4 week dosing, but not excluded for participants enrolled on every 2 week dosing. TSH=thyroid stimulating hormone.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Shifts From Baseline: Urinalysis</measure>
    <time_frame>Baseline (BIIB017 Treatment Baseline from Study 105MS301) up to 4 years</time_frame>
    <description>Shift to low includes normal to low, high to low, and unknown to low. Shift to high/positive includes normal to high/positive, low to high/positive, negative to high/positive, and unknown to high/positive. For participants who switched to alternative MS medications, data after switch and 14 days after last dose of study treatment are excluded. Data collected after Amendment 3 took effect were excluded for participants enrolled into study 105MS302 on every 4 week dosing, but not excluded for participants enrolled on every 2 week dosing. Pos=positive; RBC=red blood cells; WBC=white blood cells.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized Relapse Rate (ARR)</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Relapses are defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the examining neurologist. The annualized relapse rate is calculated as the total number of relapses occurred during the period for all participants, divided by the total number of person-years followed in the period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Relapsed</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Relapses are defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the examining neurologist. New or recurrent neurologic symptoms that occur less than 30 days following the onset of a relapse were considered part of the same relapse. Participants who did not experience a relapse prior to switching to alternative MS medications, withdrew from study, or Amendment 3 (A3) took effect were censored at the time of switch/withdrawal/A3 effective date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of New or Newly Enlarging T2 Hyperintense Lesions</measure>
    <time_frame>Week 48, Week 96</time_frame>
    <description>The total number of new or newly enlarging T2 hyperintense lesions (from Study 105MS302 Baseline) as assessed by magnetic resonance imaging (MRI). Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of New Active Lesions</measure>
    <time_frame>Week 48, Week 96</time_frame>
    <description>The number of new active lesions as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of New T1 Hypointense Lesions</measure>
    <time_frame>Week 48, Week 96</time_frame>
    <description>The total number of new T1 hypointense lesions as assessed by MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Gd-Enhancing Lesions</measure>
    <time_frame>Baseline (start of 105MS302), Week 48, Week 96</time_frame>
    <description>The number of Gd-enhancing lesions as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of T2 Hyperintense Lesions</measure>
    <time_frame>Baseline (start of 105MS302), Week 48, Week 96</time_frame>
    <description>The volume of T2 hyperintense lesions as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of T1 Hypointense Lesions</measure>
    <time_frame>Baseline (start of 105MS302), Week 48, Week 96</time_frame>
    <description>The volume of T1 hypointense lesions as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Gd-Enhancing Lesions</measure>
    <time_frame>Baseline (start of 105MS302), Week 48, Week 96</time_frame>
    <description>The volume of Gd-enhancing lesions as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change of Whole Brain Volume</measure>
    <time_frame>Baseline (start of 105MS302), Week 48, Week 96</time_frame>
    <description>Percentage change of whole brain volume as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>Baseline (start of 105MS302), Weeks 12, 24, 48, 72, 96, 120, 144, 168</time_frame>
    <description>Change from Baseline in disability as measured by the Expanded Disability Status Scale (EDSS). The EDSS measures the disability status of people with multiple sclerosis on a scale that ranges from 0 to 10. The range of main categories include (0) = normal neurologic exam; to (5) = ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to (10) = death due to MS. Data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Sustained Disability Progression</measure>
    <time_frame>Weeks 12, 24, 28, 72, 96, 120, 144, 168</time_frame>
    <description>Estimated proportion of participants with progression and time to progression based on the Kaplan-Meier product limit method. Sustained disability progression is defined as: at least a 1.0 point increase on the EDSS from 105MS302 baseline EDSS ≥ 1.0 that is sustained for 24 weeks, or at least a 1.5 point increase on the EDSS from 105MS302 baseline EDSS = 0 that is sustained for 24 weeks. The EDSS measures the disability status of people with multiple sclerosis on a scale that ranges from 0 to 10. The range of main categories include (0) = normal neurologic exam; to (5) = ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to (10) = death due to MS. Participants were censored at the time of withdrawal/switch/A3 effective date if they withdrew from study, switched to alternative MS medication, or Amendment 3 took effect without a progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Symbol Digit Modalities Test (SDMT)</measure>
    <time_frame>Baseline (start of 105MS302), Weeks 24, 48, 72, 96, 120, 144, 168</time_frame>
    <description>SDMT is a screening test for cognitive impairment. Participants are given 90 seconds in which to pair specific numbers with given geometric figures using a key. Scores range from 0 (worst) to 110 (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Multiple Sclerosis Impact Scale (MSIS)-29 Physical Score</measure>
    <time_frame>Baseline (start of 105MS302), Weeks 24, 48, 72, 96, 120, 144, 168</time_frame>
    <description>The 29-item MSIS-29 is a disease-specific participant-reported outcome measure that has been developed and validated to examine the physical and psychological impact of MS from a patient's perspective; it measures 20 physical items and 9 psychological items. Responses use a 5-point Likert scale ranging from 1 to 5. All questions are to be answered. The physical well being assessment portion of the MSIS-29 consists of 20 questions in which participants rate the impact of MS on their day-to-day life during the past two weeks from 1=no impact to 5=extreme impact for a total score of 20-100. A lower total score indicates less physically-related impact while a higher total score indicates greater physically-related impact on a participant's functioning. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 12-Item Short Form Health Survey (SF-12) Mental Component Score (MCS)</measure>
    <time_frame>Baseline (start of 105MS302), Weeks 24, 48, 72, 96, 120, 144, 168</time_frame>
    <description>The SF-12 is a multipurpose short form survey with 12 questions, all selected from the SF-36 Health Survey. The questions were combined, scored, and weighted to create two scales that provide glimpses into mental and physical functioning and overall health-related-quality of life. MCS computed using the scores of 12 questions and range from 0 to 100, where a 0 score indicates the lowest level of health and 100 indicates the highest level of health. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SF-12 Physical Component Score (PCS)</measure>
    <time_frame>Baseline (start of 105MS302), Weeks 24, 48, 72, 96, 120, 144, 168</time_frame>
    <description>The SF-12 is a multipurpose short form survey with 12 questions, all selected from the SF-36 Health Survey. The questions were combined, scored, and weighted to create two scales that provide glimpses into mental and physical functioning and overall health-related-quality of life. PCS was computed using the scores of 12 questions and range from 0 to 100, where a 0 score indicates the lowest level of health and 100 indicates the highest level of health. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Euro Quality of Life (EQ-5D) Index Score</measure>
    <time_frame>Baseline (start of 105MS302), Weeks 24, 48, 72, 96, 120, 144, 168</time_frame>
    <description>The EQ-5D is a participant-answered questionnaire scoring 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Scores of 1, 2, or 3 are possible responses for each of 5 questions (1=no problems, 2=some problems, 3=severe problems). A scoring formula developed by the EuroQol Group is then used to assign utility values for each participant's Health State Profile. A summary index score (EQ-5D index score) is derived from the 5 questions by conversion with this scoring formula and a table of scores. EQ-5D Summary Index values ranged from -0.6 (worst health state) to 1.00 (perfect health state). Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EQ-5D Visual Analogue Scale (VAS)</measure>
    <time_frame>Baseline (start of 105MS302), Weeks 24, 48, 72, 96, 120, 144, 168</time_frame>
    <description>The EQ-5D VAS records the participant's self-rated health on a scale from 0-100 where 100 is the 'best imaginable health state' and 0 is the 'worst imaginable health state.' The scale was normalized to a scale of 0 to 1, with higher values indicating a better health state. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Relapses Requiring IV Steroid Use</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of MS-Related Hospitalizations</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Participant-Reported Treatment Satisfaction: How Tolerable or Intolerable Do You Find the Medication?</measure>
    <time_frame>Year 1, Year 2, Year 3</time_frame>
    <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the question &quot;How tolerable or intolerable do you find the medication?&quot; answers were numerically rated from 1 (extremely intolerable) to 10 (extremely tolerable). Data after Amendment 3 took effect are excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Participant-Reported Treatment Satisfaction: How Convenient or Inconvenient Is It to Take Your Medication as Instructed?</measure>
    <time_frame>Year 1, Year 2, Year 3</time_frame>
    <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the question &quot;How convenient or inconvenient is it to take your medication as instructed?&quot; answers were numerically rated from 1 (extremely inconvenient) to 10 (extremely convenient). Data after Amendment 3 took effect are excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Participant-Reported Treatment Satisfaction: How Convenient or Inconvenient Is It to Take Your Medication Every 2 Weeks?</measure>
    <time_frame>Year 1, Year 2, Year 3</time_frame>
    <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the question &quot;How convenient or inconvenient is it to take your medication every 2 weeks?&quot; answers were numerically rated from 1 (extremely inconvenient) to 10 (extremely convenient). Data after Amendment 3 took effect are excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Participant-Reported Treatment Satisfaction: Overall, How Satisfied or Dissatisfied Are You With This Medication?</measure>
    <time_frame>Year 1, Year 2, Year 3</time_frame>
    <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the question &quot;Overall, how satisfied or dissatisfied are you with this medication?&quot; answers were numerically rated from 1 (extremely dissatisfied) to 10 (extremely satisfied). Data after Amendment 3 took effect are excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Participant-Reported Treatment Satisfaction: How Satisfied or Dissatisfied Are You With the Injection Frequency (Every 2 Weeks)?</measure>
    <time_frame>Year 1, Year 2, Year 3</time_frame>
    <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the question &quot;How satisfied or dissatisfied are you with the injection frequency (every 2 weeks)?&quot; answers were numerically rated from 1 (extremely dissatisfied) to 10 (extremely satisfied). Data after Amendment 3 took effect are excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Participant-Reported Treatment Satisfaction: How Likely Would You Be to Continue to Use This Medication?</measure>
    <time_frame>Year 1, Year 2, Year 3</time_frame>
    <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the question &quot;How likely would you be to continue to use this medication?&quot; answers were numerically rated from 1 (extremely unlikely) to 10 (extremely likely). Data after Amendment 3 took effect are excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Participant-Reported Treatment Satisfaction: This Medication Enables Me to Focus More on Myself and My Family Rather Than My MS.</measure>
    <time_frame>Year 1, Year 2, Year 3</time_frame>
    <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the statement &quot;This Medication Enables Me to Focus More on Myself and My Family Rather Than My MS,&quot; answers were numerically rated from 1 (strongly disagree) to 10 (strongly agree). Data after Amendment 3 took effect are excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Participant-Reported Treatment Satisfaction: This Medication Makes It Easy For Me to Carry Out My Daily Responsibilities.</measure>
    <time_frame>Year 1, Year 2, Year 3</time_frame>
    <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the statement &quot;This medication makes it easy for me to carry out my daily responsibilities (ie, going to work, doing household chores or caring for my family),&quot; answers were numerically rated from 1 (strongly disagree) to 10 (strongly agree). Data after Amendment 3 took effect are excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Participant-Reported Treatment Satisfaction: The Twice a Month Dosing Makes It More Convenient for Me to Travel/Vacation.</measure>
    <time_frame>Year 1, Year 2, Year 3</time_frame>
    <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the statement &quot;The twice a month dosing makes it more convenient for me to travel/vacation,&quot; answers were numerically rated from 1 (strongly disagree) to 10 (strongly agree). Data after Amendment 3 took effect are excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Participant-Reported Treatment Satisfaction: The Twice a Month Dosing Enables Me to Be More Spontaneous and Flexible.</measure>
    <time_frame>Year 1, Year 2, Year 3</time_frame>
    <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the statement &quot;The twice a month dosing enables me to be more spontaneous and flexible,&quot; answers were numerically rated from 1 (strongly disagree) to 10 (strongly agree). Data after Amendment 3 took effect are excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Participant-Reported Treatment Satisfaction: This Medication Improves My Self-Confidence and Self-Reliance.</measure>
    <time_frame>Year 1, Year 2, Year 3</time_frame>
    <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the statement &quot;This medication improves my self-confidence and self-reliance,&quot; answers were numerically rated from 1 (strongly disagree) to 10 (strongly agree). Data after Amendment 3 took effect are excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Participant-Reported Treatment Satisfaction: I Am Satisfied With the Dosing Frequency of This Medication.</measure>
    <time_frame>Year 1, Year 2, Year 3</time_frame>
    <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the statement &quot;I am satisfied with the dosing frequency (2 times per month) of this medication&quot; answers were numerically rated from 1 (strongly disagree) to 10 (strongly agree). Data after Amendment 3 took effect are excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Participant-Reported Treatment Satisfaction: Over the Past 4 Weeks, Did You Miss Any of Your Injections?</measure>
    <time_frame>Year 1, Year 2, Year 3</time_frame>
    <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the question &quot;Over the past 4 weeks, did you miss any of your injections?&quot; answer choices were given as &quot;none missed,&quot; &quot;miss 1 injection,&quot; or &quot;miss 2 injections.&quot; Data after Amendment 3 took effect are excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Participant-Reported Treatment Satisfaction: Main Reason for Missed Injections</measure>
    <time_frame>Year 1, Year 2, Year 3</time_frame>
    <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the question &quot;Main reason for missed injections?&quot; answer choices were given as &quot;medication side effects,&quot; &quot;injection pain,&quot; &quot;forget to take medication,&quot; &quot;tired of taking injections,&quot; &quot;don't think medication is working,&quot; or &quot;other.&quot; Data after Amendment 3 took effect are excluded.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1077</enrollment>
  <condition>Relapsing Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>peginterferon beta-1a Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>125 µg peginterferon beta-1a administered by subcutaneous (SC) injection every 4 weeks (Q4W) for at least 2 years and up to 4 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>peginterferon beta-1a Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>125 μg peginterferon beta-1a administered by SC injection every 2 weeks (Q2W) for at least 2 years and up to 4 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peginterferon beta-1a</intervention_name>
    <description>Administered as specified in the treatment arm</description>
    <arm_group_label>peginterferon beta-1a Q4W</arm_group_label>
    <arm_group_label>peginterferon beta-1a Q2W</arm_group_label>
    <other_name>PEGylated Interferon beta-1a</other_name>
    <other_name>Plegridy</other_name>
    <other_name>PEG IFN β-1a</other_name>
    <other_name>BIIB017</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Must have completed the study treatment and visit schedule through Week 96 in Study
             105MS301 (NCT00906399).

        Key Exclusion Criteria:

          -  Subjects exceeding more than 6 weeks since completion of the Week 96 visit of Study
             105MS301 (NCT00906399).

          -  Subjects with any clinically significant laboratory abnormalities, malignancies,
             cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic,
             pulmonary, neurologic, dermatologic, psychiatric, renal, or other major disease

          -  Pregnant or nursing women.

        NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30327</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40513</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607 6520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sint-Truiden</city>
        <zip>3800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1113</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1309</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago</city>
        <zip>8207257</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Havffov</city>
        <zip>73601</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrava-Vitkovice</city>
        <zip>703 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrava</city>
        <zip>708 52</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha</city>
        <zip>128 08</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Teplice</city>
        <zip>415 29</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parnu</city>
        <zip>EE 80010</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tallinn</city>
        <zip>EE 10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tartu</city>
        <zip>EE 51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bouches-du-Rhone</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nice</city>
        <zip>6002</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tbilisi</city>
        <zip>112</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tbilisi</city>
        <zip>179</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tbilisi</city>
        <zip>186</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bayreuth</city>
        <zip>95445</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10713</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Erbach</city>
        <zip>64711</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hannover</city>
        <zip>30559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koln</city>
        <zip>50935</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leipzig</city>
        <zip>4103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marberg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Prien</city>
        <zip>83209</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ulm</city>
        <zip>89079</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Westerstede</city>
        <zip>26655</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>11521</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>11525</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rajkot</city>
        <state>Gujarat</state>
        <zip>360001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indore</city>
        <state>Madhyr Pradesh</state>
        <zip>452018</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411030</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amritsar</city>
        <state>Punjab</state>
        <zip>143001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coimbatore</city>
        <state>Tamil Nadu</state>
        <zip>641014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700068</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangalore</city>
        <zip>560017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chennai</city>
        <zip>600017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mangalore</city>
        <zip>575018</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Navi Mumbai</city>
        <zip>400703</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Delhi</city>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Delhi</city>
        <zip>110060</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saket</city>
        <zip>110017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riga</city>
        <zip>LV1005</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20127</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chihuahua</city>
        <zip>31203</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heroes de Padierna</city>
        <zip>10700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico City</city>
        <zip>3600</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monterrey</city>
        <zip>64710</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dunedin</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>Lima01</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>Lima1</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>Lima21</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Isidro</city>
        <zip>Lima27</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15402</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85618</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80299</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80803</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <zip>40594</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <zip>40662</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <zip>40749</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <zip>40752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Konskie</city>
        <zip>26200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <zip>31505</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <zip>31637</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <zip>31826</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <zip>90153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <zip>20718</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <zip>20954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olsztyn</city>
        <zip>10082</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plewiska</city>
        <zip>62064</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <zip>60355</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <zip>61289</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <zip>70111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <zip>71252</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>00851</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>04141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>04749</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brasov</city>
        <zip>500123</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucharest</city>
        <zip>50098</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Campulung</city>
        <zip>115100</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sibiu</city>
        <zip>550166</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Targu Mures</city>
        <zip>540136</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaluga</city>
        <zip>248007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kazan</city>
        <zip>420021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kransodar</city>
        <zip>350012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kursk</city>
        <zip>305007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>107150</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>119021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perm</city>
        <zip>614990</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rostov-on-Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ufa</city>
        <zip>450005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nis</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cordoba</city>
        <zip>14008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seville</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49027</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Donetsk</city>
        <zip>83099</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61103</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <zip>3110</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <zip>4107</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Odesa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poltava</city>
        <zip>26011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Simferopol</city>
        <zip>95017</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ternopil</city>
        <zip>46027</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>E11BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <zip>M68HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG72UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sheffield</city>
        <zip>S108JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>India</country>
    <country>Latvia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2011</study_first_submitted>
  <study_first_submitted_qc>April 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2011</study_first_posted>
  <results_first_submitted>September 28, 2016</results_first_submitted>
  <results_first_submitted_qc>November 17, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 13, 2017</results_first_posted>
  <last_update_submitted>November 17, 2016</last_update_submitted>
  <last_update_submitted_qc>November 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Subcutaneous</keyword>
  <keyword>Extension</keyword>
  <keyword>Interferon</keyword>
  <keyword>MS</keyword>
  <keyword>PEGylated</keyword>
  <keyword>Injectable</keyword>
  <keyword>SC</keyword>
  <keyword>PEG</keyword>
  <keyword>peginterferon beta-1a</keyword>
  <keyword>Relapsing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1a</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study 105MS302 (NCT01332019) is an extension study and includes participants previously randomized to Study 105MS301 (NCT00906399). Only participants in Study 105MS301 who completed the study treatment and visit schedule through Week 96 were eligible for entry into this study.</recruitment_details>
      <pre_assignment_details>Participants continued BIIB017 at the same dosage regimen they were following during treatment year 2 of Study 105MS301: BIIB017 125 μg subcutaneously (SC) every 2 weeks (Q2W) or every 4 weeks (Q4W). A major change in study design was introduced in Amendment 3 of the protocol, which switched all ongoing subjects dosing Q4W to dosing Q2W.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>BIIB017 Q4W</title>
          <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
        </group>
        <group group_id="P2">
          <title>BIIB017 Q2W</title>
          <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="530"/>
                <participants group_id="P2" count="547"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="417"/>
                <participants group_id="P2" count="425"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
                <participants group_id="P2" count="122"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Was Not Dosed</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat (ITT) population: who entered Study 105MS302 and received at least 1 dose of study treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>BIIB017 Q4W</title>
          <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
        </group>
        <group group_id="B2">
          <title>BIIB017 Q2W</title>
          <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="529"/>
            <count group_id="B2" value="547"/>
            <count group_id="B3" value="1076"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.1" spread="9.95"/>
                    <measurement group_id="B2" value="38.7" spread="9.59"/>
                    <measurement group_id="B3" value="38.4" spread="9.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>20-29 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30-39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40-49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="172"/>
                    <measurement group_id="B3" value="322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50-59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="378"/>
                    <measurement group_id="B2" value="397"/>
                    <measurement group_id="B3" value="775"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Adverse Events (AEs) Serious AEs, and Discontinuations Due to AEs</title>
        <description>AE: any untoward medical occurrence that did not necessarily have a causal relationship with study treatment. SAE: any untoward medical occurrence that at any dose: resulted in death; in the view of the Investigator, placed the participant at immediate risk of death (a life threatening event); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect; any other medically important event that, in the opinion of the Investigator, could have jeopardized the participant or may have required intervention to prevent one of the other outcomes listed in the definition above. Data collected after Amendment 3 took effect were excluded for participants enrolled into study 105MS302 on every 4 week dosing, but not excluded for participants enrolled on every 2 week dosing.</description>
        <time_frame>up to 4 years</time_frame>
        <population>Safety population: all participants who received at least 1 dose of study drug. For participants who switched to alternative MS medications, data after switch and 14 days after last dose of study treatment are excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Adverse Events (AEs) Serious AEs, and Discontinuations Due to AEs</title>
          <description>AE: any untoward medical occurrence that did not necessarily have a causal relationship with study treatment. SAE: any untoward medical occurrence that at any dose: resulted in death; in the view of the Investigator, placed the participant at immediate risk of death (a life threatening event); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect; any other medically important event that, in the opinion of the Investigator, could have jeopardized the participant or may have required intervention to prevent one of the other outcomes listed in the definition above. Data collected after Amendment 3 took effect were excluded for participants enrolled into study 105MS302 on every 4 week dosing, but not excluded for participants enrolled on every 2 week dosing.</description>
          <population>Safety population: all participants who received at least 1 dose of study drug. For participants who switched to alternative MS medications, data after switch and 14 days after last dose of study treatment are excluded.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="471"/>
                    <measurement group_id="O2" value="478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate or severe event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="343"/>
                    <measurement group_id="O2" value="348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Event related to study treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="400"/>
                    <measurement group_id="O2" value="399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuing study treatment due to an event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawing from study due to an event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Potentially Clinically Significant Hematology Laboratory Abnormalities</title>
        <description>Data collected after Amendment 3 took effect were excluded for participants enrolled into study 105MS302 on every 4 week dosing, but not excluded for participants enrolled on every 2 week dosing.</description>
        <time_frame>up to 4 years</time_frame>
        <population>Safety population: all participants who received at least 1 dose of study drug and at least 1 post-baseline value for given parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Potentially Clinically Significant Hematology Laboratory Abnormalities</title>
          <description>Data collected after Amendment 3 took effect were excluded for participants enrolled into study 105MS302 on every 4 week dosing, but not excluded for participants enrolled on every 2 week dosing.</description>
          <population>Safety population: all participants who received at least 1 dose of study drug and at least 1 post-baseline value for given parameter.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="528"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>White blood cells &lt; 3.0*10^9/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White blood cells ≥ 16.0*10^9/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes &lt; 0.8*10^9/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes &lt; 0.5*10^9/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes &gt; 12*10^9/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Segmented neutrophils ≤ 1*10^9/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Segmented neutrophils &lt; 1.5*10^9/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Segmented neutrophils ≥ 12*10^9/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total absolute neutrophils ≤ 1*10^9/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total absolute neutrophils &lt; 1.5*10^9/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total absolute neutrophils ≥ 12*10^9/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cells ≤ 3.3*10^12/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cells ≥ 6.8*10^12/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin ≤ 100 g/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count ≤ 100*10^9/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count ≥ 600*10^9/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Shifts From Baseline: Liver Function Laboratory Values</title>
        <description>Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high. For participants who switched to alternative MS medications, data after switch and 14 days after last dose of study treatment are excluded. Data collected after Amendment 3 took effect were excluded for participants enrolled into study 105MS302 on every 4 week dosing, but not excluded for participants enrolled on every 2 week dosing. ALT=alanine aminotransferase; AST=aspartate aminotransferase; GGT=gamma-glutamyl transferase.</description>
        <time_frame>Baseline (BIIB017 Treatment Baseline from Study 105MS301) up to 4 years</time_frame>
        <population>Safety population: all participants who received at least 1 dose of study drug; n=number of participants whose baseline value was not low (or high) and who had at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Shifts From Baseline: Liver Function Laboratory Values</title>
          <description>Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high. For participants who switched to alternative MS medications, data after switch and 14 days after last dose of study treatment are excluded. Data collected after Amendment 3 took effect were excluded for participants enrolled into study 105MS302 on every 4 week dosing, but not excluded for participants enrolled on every 2 week dosing. ALT=alanine aminotransferase; AST=aspartate aminotransferase; GGT=gamma-glutamyl transferase.</description>
          <population>Safety population: all participants who received at least 1 dose of study drug; n=number of participants whose baseline value was not low (or high) and who had at least 1 post-baseline value.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT: shift to low; n=528, 546</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT: shift to high; n=487, 497</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST: shift to low; n=528, 546</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST: shift to high; n=514, 530</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin: shift to low; n=512, 517</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin: shift to high; n=511, 535</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT: shift to low; n=529, 545</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT: shift to high; n=512, 528</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase: shift to low; n=522, 543</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase: shift to high; n=516, 536</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactate dehydrogenase: shift to low; n=529, 547</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactate dehydrogenase: shift to high; n=524, 541</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Shifts From Baseline: Kidney Function and Other Blood Chemistry</title>
        <description>Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high. For participants who switched to alternative MS medications, data after switch and 14 days after last dose of study treatment are excluded. Data collected after Amendment 3 took effect were excluded for participants enrolled into study 105MS302 on every 4 week dosing, but not excluded for participants enrolled on every 2 week dosing. TSH=thyroid stimulating hormone.</description>
        <time_frame>Baseline (BIIB017 Treatment Baseline from Study 105MS301) up to 4 years</time_frame>
        <population>Safety population: all participants who received at least 1 dose of study drug; n=number of participants whose baseline value was not low (or high) and who had at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Shifts From Baseline: Kidney Function and Other Blood Chemistry</title>
          <description>Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high. For participants who switched to alternative MS medications, data after switch and 14 days after last dose of study treatment are excluded. Data collected after Amendment 3 took effect were excluded for participants enrolled into study 105MS302 on every 4 week dosing, but not excluded for participants enrolled on every 2 week dosing. TSH=thyroid stimulating hormone.</description>
          <population>Safety population: all participants who received at least 1 dose of study drug; n=number of participants whose baseline value was not low (or high) and who had at least 1 post-baseline value.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood urea nitrogen: shift to low; n=529, 546</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood urea nitrogen: shift to high; n=527, 543</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine: shift to low; n=529, 547</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine: shift to high; n=528, 545</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate: shift to low; n=523, 540</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate: shift to high; n=529, 544</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium: shift to low; n=529, 546</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium: shift to high; n=524, 544</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium: shift to low; n=527, 544</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium: shift to high; n=528, 546</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride: shift to low; n=529, 546</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride: shift to high; n=528, 547</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose: shift to low; n=522, 539</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose: shift to high; n=506, 513</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="304"/>
                    <measurement group_id="O2" value="311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSH: shift to low; n=515, 533</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSH: shift to high; n=518, 539</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Shifts From Baseline: Urinalysis</title>
        <description>Shift to low includes normal to low, high to low, and unknown to low. Shift to high/positive includes normal to high/positive, low to high/positive, negative to high/positive, and unknown to high/positive. For participants who switched to alternative MS medications, data after switch and 14 days after last dose of study treatment are excluded. Data collected after Amendment 3 took effect were excluded for participants enrolled into study 105MS302 on every 4 week dosing, but not excluded for participants enrolled on every 2 week dosing. Pos=positive; RBC=red blood cells; WBC=white blood cells.</description>
        <time_frame>Baseline (BIIB017 Treatment Baseline from Study 105MS301) up to 4 years</time_frame>
        <population>Safety population: all participants who received at least 1 dose of study drug; n=number of participants whose baseline value was not low or high/positive and who had at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Shifts From Baseline: Urinalysis</title>
          <description>Shift to low includes normal to low, high to low, and unknown to low. Shift to high/positive includes normal to high/positive, low to high/positive, negative to high/positive, and unknown to high/positive. For participants who switched to alternative MS medications, data after switch and 14 days after last dose of study treatment are excluded. Data collected after Amendment 3 took effect were excluded for participants enrolled into study 105MS302 on every 4 week dosing, but not excluded for participants enrolled on every 2 week dosing. Pos=positive; RBC=red blood cells; WBC=white blood cells.</description>
          <population>Safety population: all participants who received at least 1 dose of study drug; n=number of participants whose baseline value was not low or high/positive and who had at least 1 post-baseline value.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Specific gravity: shift to low; n=525, 545</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specific gravity: shift to high/pos; n=528,547</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pH: shift to low; n=529, 547</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pH: shift to high/pos; n=528, 547</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Color: shift to high/pos; n=516, 529</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood: shift to high/pos; n=469, 495</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159"/>
                    <measurement group_id="O2" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose: shift to high/pos; n=521, 542</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketones: shift to high/pos; n=510, 530</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein: shift to high/pos; n=380, 391</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270"/>
                    <measurement group_id="O2" value="277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC: shift to high/pos; n=419, 402</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC: shift to high/pos; n=472, 495</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin: shift to high/pos; n=529, 547</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nitrite: shift to high/pos; n=508, 519</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urobilinogen: shift to high/pos; n=529, 546</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Relapse Rate (ARR)</title>
        <description>Relapses are defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the examining neurologist. The annualized relapse rate is calculated as the total number of relapses occurred during the period for all participants, divided by the total number of person-years followed in the period.</description>
        <time_frame>up to 4 years</time_frame>
        <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Relapse Rate (ARR)</title>
          <description>Relapses are defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the examining neurologist. The annualized relapse rate is calculated as the total number of relapses occurred during the period for all participants, divided by the total number of person-years followed in the period.</description>
          <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment.</population>
          <units>relapses per person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Relapses</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Relapses</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="232"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.189" lower_limit="0.154" upper_limit="0.231"/>
                    <measurement group_id="O2" value="0.142" lower_limit="0.114" upper_limit="0.177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Based on negative binomial regression for each treatment group, with adjustment for EDSS (&lt;4 vs. &gt;=4), relapse rate (based on 1 year before 105MS301 and 105MS301), and age (&lt;40 vs. &gt;=40) at 105MS302 baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0203</p_value>
            <p_value_desc>q2w/q4w</p_value_desc>
            <method>negative binomial regression</method>
            <param_type>rate ratio</param_type>
            <param_value>0.755</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.595</ci_lower_limit>
            <ci_upper_limit>0.957</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Relapsed</title>
        <description>Relapses are defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the examining neurologist. New or recurrent neurologic symptoms that occur less than 30 days following the onset of a relapse were considered part of the same relapse. Participants who did not experience a relapse prior to switching to alternative MS medications, withdrew from study, or Amendment 3 (A3) took effect were censored at the time of switch/withdrawal/A3 effective date.</description>
        <time_frame>Up to 4 years</time_frame>
        <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Relapsed</title>
          <description>Relapses are defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the examining neurologist. New or recurrent neurologic symptoms that occur less than 30 days following the onset of a relapse were considered part of the same relapse. Participants who did not experience a relapse prior to switching to alternative MS medications, withdrew from study, or Amendment 3 (A3) took effect were censored at the time of switch/withdrawal/A3 effective date.</description>
          <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Did not relapse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relapsed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>q2w/q4w</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0201</p_value>
            <p_value_desc>Based on Cox proportion hazards model, adjusted for EDSS (&lt;4 vs &gt;= 4), age (&lt;40 vs &gt;=40), relapse rate (based on one year before 105MS301 and 105MS301), and gadolinium (Gd) enhancing lesions (presence vs. absence) at 105MS302 baseline.</p_value_desc>
            <method>Cox proportion hazards model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of New or Newly Enlarging T2 Hyperintense Lesions</title>
        <description>The total number of new or newly enlarging T2 hyperintense lesions (from Study 105MS302 Baseline) as assessed by magnetic resonance imaging (MRI). Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
        <time_frame>Week 48, Week 96</time_frame>
        <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=number of participants with an assessment at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of New or Newly Enlarging T2 Hyperintense Lesions</title>
          <description>The total number of new or newly enlarging T2 hyperintense lesions (from Study 105MS302 Baseline) as assessed by magnetic resonance imaging (MRI). Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
          <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=number of participants with an assessment at given timepoint.</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="481"/>
                <count group_id="O2" value="493"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48; n=481, 493</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="8.19"/>
                    <measurement group_id="O2" value="1.9" spread="4.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96; n=411, 407</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" spread="16.64"/>
                    <measurement group_id="O2" value="3.9" spread="9.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Lesion mean ratio (95% CI) and p-value for comparison between the every 2 weeks group and the every 4 weeks group, based on negative binomial regression, adjusted for 105MS302 baseline number of T2 lesions.</p_value_desc>
            <method>negative binomial regression</method>
            <param_type>lesion mean ratio</param_type>
            <param_value>0.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.41</ci_lower_limit>
            <ci_upper_limit>0.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 96</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Lesion mean ratio (95% CI) and p-value for comparison between the every 2 weeks group and the every 4 weeks group, based on negative binomial regression, adjusted for 302 baseline number of T2 lesions.</p_value_desc>
            <method>negative binomial regression</method>
            <param_type>lesion mean ratio</param_type>
            <param_value>0.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>0.62</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of New Active Lesions</title>
        <description>The number of new active lesions as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
        <time_frame>Week 48, Week 96</time_frame>
        <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=number of participants with an assessment at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of New Active Lesions</title>
          <description>The number of new active lesions as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
          <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=number of participants with an assessment at given timepoint.</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48; n=481, 493</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="8.25"/>
                    <measurement group_id="O2" value="2.0" spread="4.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96; n=411, 406</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" spread="16.88"/>
                    <measurement group_id="O2" value="3.9" spread="9.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Lesion mean ratio (95% CI) and p-value for comparison between the every 2 weeks group and the every 4 weeks group, based on negative binomial regression, adjusted for 105MS302 baseline number of Gd lesions.</p_value_desc>
            <method>negative binomial regression</method>
            <param_type>lesion mean ratio</param_type>
            <param_value>0.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>0.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 96</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Lesion mean ratio (95% CI) and p-value for comparison between the every 2 weeks group and the every 4 weeks group, based on negative binomial regression, adjusted for 105MS302 baseline number of Gd lesions.</p_value_desc>
            <method>negative binomial regression</method>
            <param_type>lesion mean ratio</param_type>
            <param_value>0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>0.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of New T1 Hypointense Lesions</title>
        <description>The total number of new T1 hypointense lesions as assessed by MRI.</description>
        <time_frame>Week 48, Week 96</time_frame>
        <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=number of participants with an assessment at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of New T1 Hypointense Lesions</title>
          <description>The total number of new T1 hypointense lesions as assessed by MRI.</description>
          <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=number of participants with an assessment at given timepoint.</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 49; n=481, 493</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="3.02"/>
                    <measurement group_id="O2" value="0.8" spread="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96; n=411, 406</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="5.92"/>
                    <measurement group_id="O2" value="1.5" spread="4.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p-value for comparison between the every 2 weeks group and the every 4 weeks group, based on multiple logit regression, adjusted for 302 baseline number of T1 lesions.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 96</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p-value for comparison between the every 2 weeks group and the every 4 weeks group, based on multiple logit regression, adjusted for 302 baseline number of T1 lesions.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Gd-Enhancing Lesions</title>
        <description>The number of Gd-enhancing lesions as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
        <time_frame>Baseline (start of 105MS302), Week 48, Week 96</time_frame>
        <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=number of participants with an assessment at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Gd-Enhancing Lesions</title>
          <description>The number of Gd-enhancing lesions as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
          <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=number of participants with an assessment at given timepoint.</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline; n=528, 543</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.85"/>
                    <measurement group_id="O2" value="0.2" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48; n=481, 493</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="2.07"/>
                    <measurement group_id="O2" value="0.2" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96; n=411, 407</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="2.59"/>
                    <measurement group_id="O2" value="0.2" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <p_value_desc>p-value for comparison between the every 2 weeks group and the every 4 weeks group, based on multiple logit regression, adjusted for 302 baseline number of Gd-enhancing lesion.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 96</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0026</p_value>
            <p_value_desc>p-value for comparison between the every 2 weeks group and the every 4 weeks group, based on multiple logit regression, adjusted for 302 baseline number of Gd-enhancing lesion.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of T2 Hyperintense Lesions</title>
        <description>The volume of T2 hyperintense lesions as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
        <time_frame>Baseline (start of 105MS302), Week 48, Week 96</time_frame>
        <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=number of participants with an assessment at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of T2 Hyperintense Lesions</title>
          <description>The volume of T2 hyperintense lesions as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
          <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=number of participants with an assessment at given timepoint.</population>
          <units>cm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline; n=528, 543</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4742" spread="13.55811"/>
                    <measurement group_id="O2" value="9.9678" spread="11.41807"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48; n=481, 493</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7421" spread="13.91774"/>
                    <measurement group_id="O2" value="9.8335" spread="11.05029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96; n=411, 407</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0257" spread="13.91056"/>
                    <measurement group_id="O2" value="9.9487" spread="10.97208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of T1 Hypointense Lesions</title>
        <description>The volume of T1 hypointense lesions as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
        <time_frame>Baseline (start of 105MS302), Week 48, Week 96</time_frame>
        <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=number of participants with an assessment at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of T1 Hypointense Lesions</title>
          <description>The volume of T1 hypointense lesions as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
          <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=number of participants with an assessment at given timepoint.</population>
          <units>cm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline; n=528, 543</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9869" spread="6.29557"/>
                    <measurement group_id="O2" value="3.6320" spread="5.47465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48; n=481, 493</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3062" spread="6.92839"/>
                    <measurement group_id="O2" value="3.6529" spread="5.19027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96; n=411, 407</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3171" spread="6.70107"/>
                    <measurement group_id="O2" value="3.7494" spread="5.21314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Gd-Enhancing Lesions</title>
        <description>The volume of Gd-enhancing lesions as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
        <time_frame>Baseline (start of 105MS302), Week 48, Week 96</time_frame>
        <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=number of participants with an assessment at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Gd-Enhancing Lesions</title>
          <description>The volume of Gd-enhancing lesions as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
          <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=number of participants with an assessment at given timepoint.</population>
          <units>cm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline; n=528, 543</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0911" spread="0.30013"/>
                    <measurement group_id="O2" value="0.0348" spread="0.17344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48; n=481, 493</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1172" spread="0.42762"/>
                    <measurement group_id="O2" value="0.0477" spread="0.31479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96; n=411, 407</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1346" spread="0.50580"/>
                    <measurement group_id="O2" value="0.0357" spread="0.14976"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change of Whole Brain Volume</title>
        <description>Percentage change of whole brain volume as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
        <time_frame>Baseline (start of 105MS302), Week 48, Week 96</time_frame>
        <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=number of participants with an assessment at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change of Whole Brain Volume</title>
          <description>Percentage change of whole brain volume as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
          <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=number of participants with an assessment at given timepoint.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 48; n=402, 418</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.522" spread="0.6205"/>
                    <measurement group_id="O2" value="-0.453" spread="0.8127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 96; n=365, 358</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.835" spread="1.0785"/>
                    <measurement group_id="O2" value="-0.788" spread="1.1912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Expanded Disability Status Scale (EDSS)</title>
        <description>Change from Baseline in disability as measured by the Expanded Disability Status Scale (EDSS). The EDSS measures the disability status of people with multiple sclerosis on a scale that ranges from 0 to 10. The range of main categories include (0) = normal neurologic exam; to (5) = ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to (10) = death due to MS. Data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
        <time_frame>Baseline (start of 105MS302), Weeks 12, 24, 48, 72, 96, 120, 144, 168</time_frame>
        <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=number of participants with an assessment at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Expanded Disability Status Scale (EDSS)</title>
          <description>Change from Baseline in disability as measured by the Expanded Disability Status Scale (EDSS). The EDSS measures the disability status of people with multiple sclerosis on a scale that ranges from 0 to 10. The range of main categories include (0) = normal neurologic exam; to (5) = ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to (10) = death due to MS. Data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
          <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=number of participants with an assessment at given timepoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline; n=516, 535</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.43" spread="1.346"/>
                    <measurement group_id="O2" value="2.35" spread="1.299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12; n=503, 524</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.388"/>
                    <measurement group_id="O2" value="0.00" spread="0.450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24; n=500, 519</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.449"/>
                    <measurement group_id="O2" value="0.00" spread="0.486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48; n=488, 497</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.564"/>
                    <measurement group_id="O2" value="0.03" spread="0.510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 72; n=468, 484</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.629"/>
                    <measurement group_id="O2" value="0.06" spread="0.484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 96; n=429, 446</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.618"/>
                    <measurement group_id="O2" value="0.09" spread="0.563"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 120; n=187, 205</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.700"/>
                    <measurement group_id="O2" value="0.10" spread="0.538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 144; n=90, 98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.720"/>
                    <measurement group_id="O2" value="0.10" spread="0.587"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 168; n=21, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.889"/>
                    <measurement group_id="O2" value="0.18" spread="0.454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Sustained Disability Progression</title>
        <description>Estimated proportion of participants with progression and time to progression based on the Kaplan-Meier product limit method. Sustained disability progression is defined as: at least a 1.0 point increase on the EDSS from 105MS302 baseline EDSS ≥ 1.0 that is sustained for 24 weeks, or at least a 1.5 point increase on the EDSS from 105MS302 baseline EDSS = 0 that is sustained for 24 weeks. The EDSS measures the disability status of people with multiple sclerosis on a scale that ranges from 0 to 10. The range of main categories include (0) = normal neurologic exam; to (5) = ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to (10) = death due to MS. Participants were censored at the time of withdrawal/switch/A3 effective date if they withdrew from study, switched to alternative MS medication, or Amendment 3 took effect without a progression.</description>
        <time_frame>Weeks 12, 24, 28, 72, 96, 120, 144, 168</time_frame>
        <population>Participants in the ITT population (all participants who were assigned a treatment and received at least 1 dose of study treatment) with disability progression.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Sustained Disability Progression</title>
          <description>Estimated proportion of participants with progression and time to progression based on the Kaplan-Meier product limit method. Sustained disability progression is defined as: at least a 1.0 point increase on the EDSS from 105MS302 baseline EDSS ≥ 1.0 that is sustained for 24 weeks, or at least a 1.5 point increase on the EDSS from 105MS302 baseline EDSS = 0 that is sustained for 24 weeks. The EDSS measures the disability status of people with multiple sclerosis on a scale that ranges from 0 to 10. The range of main categories include (0) = normal neurologic exam; to (5) = ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to (10) = death due to MS. Participants were censored at the time of withdrawal/switch/A3 effective date if they withdrew from study, switched to alternative MS medication, or Amendment 3 took effect without a progression.</description>
          <population>Participants in the ITT population (all participants who were assigned a treatment and received at least 1 dose of study treatment) with disability progression.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Progressed at 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.023"/>
                    <measurement group_id="O2" value="0.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressed at 24 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.046"/>
                    <measurement group_id="O2" value="0.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressed at 48 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.079"/>
                    <measurement group_id="O2" value="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressed at 72 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.103"/>
                    <measurement group_id="O2" value="0.057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressed at 96 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.115"/>
                    <measurement group_id="O2" value="0.069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressed at 120 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.147"/>
                    <measurement group_id="O2" value="0.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressed at 144 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.161"/>
                    <measurement group_id="O2" value="0.096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressed at 168 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Estimated proportion is not calculated if the number of participants at risk is less than 30.</measurement>
                    <measurement group_id="O2" value="NA">Estimated proportion is not calculated if the number of participants at risk is less than 30.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0060</p_value>
            <p_value_desc>Based on Cox Proportional Hazards model, adjusted for 105MS302 baseline EDSS and age (&lt;40 vs &gt;=40).</p_value_desc>
            <method>Cox Proportional Hazards model</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
            <estimate_desc>q2w/q4w</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Symbol Digit Modalities Test (SDMT)</title>
        <description>SDMT is a screening test for cognitive impairment. Participants are given 90 seconds in which to pair specific numbers with given geometric figures using a key. Scores range from 0 (worst) to 110 (best).</description>
        <time_frame>Baseline (start of 105MS302), Weeks 24, 48, 72, 96, 120, 144, 168</time_frame>
        <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Symbol Digit Modalities Test (SDMT)</title>
          <description>SDMT is a screening test for cognitive impairment. Participants are given 90 seconds in which to pair specific numbers with given geometric figures using a key. Scores range from 0 (worst) to 110 (best).</description>
          <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline; n=523, 543</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.134" spread="17.7653"/>
                    <measurement group_id="O2" value="52.744" spread="17.6994"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24; n=508, 530</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.313" spread="8.5862"/>
                    <measurement group_id="O2" value="-1.106" spread="8.1292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48; n=493, 509</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.365" spread="9.3557"/>
                    <measurement group_id="O2" value="-0.864" spread="8.6059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 72; n=472, 489</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.625" spread="8.8037"/>
                    <measurement group_id="O2" value="-1.012" spread="8.5038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 96; n=435, 450</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.340" spread="8.7817"/>
                    <measurement group_id="O2" value="-0.231" spread="9.3148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 120; n=190, 203</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.305" spread="8.9248"/>
                    <measurement group_id="O2" value="-1.099" spread="9.5425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 144; n=88, 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.727" spread="7.7900"/>
                    <measurement group_id="O2" value="-0.906" spread="10.8367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 168; n=21, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.000" spread="10.4403"/>
                    <measurement group_id="O2" value="-3.840" spread="13.4712"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Multiple Sclerosis Impact Scale (MSIS)-29 Physical Score</title>
        <description>The 29-item MSIS-29 is a disease-specific participant-reported outcome measure that has been developed and validated to examine the physical and psychological impact of MS from a patient’s perspective; it measures 20 physical items and 9 psychological items. Responses use a 5-point Likert scale ranging from 1 to 5. All questions are to be answered. The physical well being assessment portion of the MSIS-29 consists of 20 questions in which participants rate the impact of MS on their day-to-day life during the past two weeks from 1=no impact to 5=extreme impact for a total score of 20-100. A lower total score indicates less physically-related impact while a higher total score indicates greater physically-related impact on a participant's functioning. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
        <time_frame>Baseline (start of 105MS302), Weeks 24, 48, 72, 96, 120, 144, 168</time_frame>
        <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Multiple Sclerosis Impact Scale (MSIS)-29 Physical Score</title>
          <description>The 29-item MSIS-29 is a disease-specific participant-reported outcome measure that has been developed and validated to examine the physical and psychological impact of MS from a patient’s perspective; it measures 20 physical items and 9 psychological items. Responses use a 5-point Likert scale ranging from 1 to 5. All questions are to be answered. The physical well being assessment portion of the MSIS-29 consists of 20 questions in which participants rate the impact of MS on their day-to-day life during the past two weeks from 1=no impact to 5=extreme impact for a total score of 20-100. A lower total score indicates less physically-related impact while a higher total score indicates greater physically-related impact on a participant's functioning. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
          <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline; n=527, 544</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.494" spread="19.8290"/>
                    <measurement group_id="O2" value="20.218" spread="19.0264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24; n=513, 534</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.152" spread="9.3332"/>
                    <measurement group_id="O2" value="0.552" spread="10.0147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48; n=498, 510</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.462" spread="10.7054"/>
                    <measurement group_id="O2" value="0.545" spread="10.6342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 72; n=474, 491</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.937" spread="11.5682"/>
                    <measurement group_id="O2" value="0.684" spread="12.4690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 96; n=437, 452</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.471" spread="10.8997"/>
                    <measurement group_id="O2" value="1.190" spread="11.4005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 120; n=193, 205</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.654" spread="14.2983"/>
                    <measurement group_id="O2" value="0.116" spread="10.4382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 144; n=88, 98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.327" spread="10.5888"/>
                    <measurement group_id="O2" value="0.051" spread="12.1417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 168; n=20, 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.250" spread="7.3292"/>
                    <measurement group_id="O2" value="-0.288" spread="13.5615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 12-Item Short Form Health Survey (SF-12) Mental Component Score (MCS)</title>
        <description>The SF-12 is a multipurpose short form survey with 12 questions, all selected from the SF-36 Health Survey. The questions were combined, scored, and weighted to create two scales that provide glimpses into mental and physical functioning and overall health-related-quality of life. MCS computed using the scores of 12 questions and range from 0 to 100, where a 0 score indicates the lowest level of health and 100 indicates the highest level of health. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
        <time_frame>Baseline (start of 105MS302), Weeks 24, 48, 72, 96, 120, 144, 168</time_frame>
        <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 12-Item Short Form Health Survey (SF-12) Mental Component Score (MCS)</title>
          <description>The SF-12 is a multipurpose short form survey with 12 questions, all selected from the SF-36 Health Survey. The questions were combined, scored, and weighted to create two scales that provide glimpses into mental and physical functioning and overall health-related-quality of life. MCS computed using the scores of 12 questions and range from 0 to 100, where a 0 score indicates the lowest level of health and 100 indicates the highest level of health. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
          <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline; n=527, 544</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.803" spread="10.2111"/>
                    <measurement group_id="O2" value="48.591" spread="10.3624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24; n=514, 535</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.396" spread="7.5967"/>
                    <measurement group_id="O2" value="-0.734" spread="8.3567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48; n=498, 510</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.409" spread="8.4442"/>
                    <measurement group_id="O2" value="-0.690" spread="8.3903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 72; n=474, 491</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.242" spread="9.3223"/>
                    <measurement group_id="O2" value="-0.162" spread="9.0676"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 96; n=437, 452</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.141" spread="9.4833"/>
                    <measurement group_id="O2" value="0.014" spread="8.8856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 120; n=193, 205</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.223" spread="10.4664"/>
                    <measurement group_id="O2" value="0.616" spread="7.5313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 144; n=88, 98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.346" spread="8.6814"/>
                    <measurement group_id="O2" value="0.110" spread="8.0301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 168; n=20, 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.451" spread="8.8575"/>
                    <measurement group_id="O2" value="0.294" spread="9.7505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SF-12 Physical Component Score (PCS)</title>
        <description>The SF-12 is a multipurpose short form survey with 12 questions, all selected from the SF-36 Health Survey. The questions were combined, scored, and weighted to create two scales that provide glimpses into mental and physical functioning and overall health-related-quality of life. PCS was computed using the scores of 12 questions and range from 0 to 100, where a 0 score indicates the lowest level of health and 100 indicates the highest level of health. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
        <time_frame>Baseline (start of 105MS302), Weeks 24, 48, 72, 96, 120, 144, 168</time_frame>
        <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SF-12 Physical Component Score (PCS)</title>
          <description>The SF-12 is a multipurpose short form survey with 12 questions, all selected from the SF-36 Health Survey. The questions were combined, scored, and weighted to create two scales that provide glimpses into mental and physical functioning and overall health-related-quality of life. PCS was computed using the scores of 12 questions and range from 0 to 100, where a 0 score indicates the lowest level of health and 100 indicates the highest level of health. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
          <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline; n=527, 544</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.154" spread="9.4474"/>
                    <measurement group_id="O2" value="44.902" spread="9.9312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24; n=514, 535</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.138" spread="6.0841"/>
                    <measurement group_id="O2" value="0.337" spread="5.7878"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48; n=498, 510</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.351" spread="6.1785"/>
                    <measurement group_id="O2" value="0.214" spread="5.8377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 72; n=474, 491</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.270" spread="6.6319"/>
                    <measurement group_id="O2" value="-0.169" spread="6.3824"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 96; n=437, 452</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.150" spread="6.6971"/>
                    <measurement group_id="O2" value="-0.138" spread="6.4453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 120; n=193, 205</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.118" spread="7.8826"/>
                    <measurement group_id="O2" value="0.021" spread="6.1354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 144; n=88, 98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.256" spread="5.7252"/>
                    <measurement group_id="O2" value="0.118" spread="6.7830"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 168; n=20, 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.558" spread="7.6525"/>
                    <measurement group_id="O2" value="0.152" spread="7.5206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Euro Quality of Life (EQ-5D) Index Score</title>
        <description>The EQ-5D is a participant-answered questionnaire scoring 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Scores of 1, 2, or 3 are possible responses for each of 5 questions (1=no problems, 2=some problems, 3=severe problems). A scoring formula developed by the EuroQol Group is then used to assign utility values for each participant’s Health State Profile. A summary index score (EQ-5D index score) is derived from the 5 questions by conversion with this scoring formula and a table of scores. EQ-5D Summary Index values ranged from -0.6 (worst health state) to 1.00 (perfect health state). Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
        <time_frame>Baseline (start of 105MS302), Weeks 24, 48, 72, 96, 120, 144, 168</time_frame>
        <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Euro Quality of Life (EQ-5D) Index Score</title>
          <description>The EQ-5D is a participant-answered questionnaire scoring 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Scores of 1, 2, or 3 are possible responses for each of 5 questions (1=no problems, 2=some problems, 3=severe problems). A scoring formula developed by the EuroQol Group is then used to assign utility values for each participant’s Health State Profile. A summary index score (EQ-5D index score) is derived from the 5 questions by conversion with this scoring formula and a table of scores. EQ-5D Summary Index values ranged from -0.6 (worst health state) to 1.00 (perfect health state). Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
          <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline; n=527, 544</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="0.230"/>
                    <measurement group_id="O2" value="0.76" spread="0.230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24; n=514, 534</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.159"/>
                    <measurement group_id="O2" value="0.00" spread="0.171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48; n=498, 510</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.159"/>
                    <measurement group_id="O2" value="0.00" spread="0.171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 72; n=472, 491</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.158"/>
                    <measurement group_id="O2" value="0.00" spread="0.179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 96; n=436, 452</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.156"/>
                    <measurement group_id="O2" value="-0.01" spread="0.195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 120; n=193, 205</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.190"/>
                    <measurement group_id="O2" value="0.00" spread="0.165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 144; n=88, 98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.169"/>
                    <measurement group_id="O2" value="0.01" spread="0.166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 168; n=21, 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.080"/>
                    <measurement group_id="O2" value="0.02" spread="0.137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in EQ-5D Visual Analogue Scale (VAS)</title>
        <description>The EQ-5D VAS records the participant's self-rated health on a scale from 0-100 where 100 is the 'best imaginable health state' and 0 is the 'worst imaginable health state.' The scale was normalized to a scale of 0 to 1, with higher values indicating a better health state. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
        <time_frame>Baseline (start of 105MS302), Weeks 24, 48, 72, 96, 120, 144, 168</time_frame>
        <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EQ-5D Visual Analogue Scale (VAS)</title>
          <description>The EQ-5D VAS records the participant's self-rated health on a scale from 0-100 where 100 is the 'best imaginable health state' and 0 is the 'worst imaginable health state.' The scale was normalized to a scale of 0 to 1, with higher values indicating a better health state. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
          <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline; n=527, 542</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.07" spread="17.623"/>
                    <measurement group_id="O2" value="77.33" spread="18.348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24; n=511, 532</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="11.411"/>
                    <measurement group_id="O2" value="-0.98" spread="12.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48; n=498, 508</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.81" spread="12.828"/>
                    <measurement group_id="O2" value="-0.93" spread="12.719"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 72; n=472, 490</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="12.735"/>
                    <measurement group_id="O2" value="-1.89" spread="15.270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 96; n=436, 450</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.10" spread="14.266"/>
                    <measurement group_id="O2" value="-2.20" spread="14.095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 120; n=193, 204</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="12.714"/>
                    <measurement group_id="O2" value="-0.88" spread="12.793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 144; n=88, 97</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="14.247"/>
                    <measurement group_id="O2" value="-0.87" spread="14.865"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 168; n=21, 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread="14.925"/>
                    <measurement group_id="O2" value="0.46" spread="12.602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Relapses Requiring IV Steroid Use</title>
        <description>Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
        <time_frame>up to 4 years</time_frame>
        <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Relapses Requiring IV Steroid Use</title>
          <description>Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
          <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment</population>
          <units>relapses</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217"/>
                    <measurement group_id="O2" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of MS-Related Hospitalizations</title>
        <description>Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
        <time_frame>up to 4 years</time_frame>
        <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of MS-Related Hospitalizations</title>
          <description>Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.</description>
          <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment</population>
          <units>hospitalizations</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Participant-Reported Treatment Satisfaction: How Tolerable or Intolerable Do You Find the Medication?</title>
        <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant’s perception of treatment satisfaction at the end of each year of treatment. For the question &quot;How tolerable or intolerable do you find the medication?&quot; answers were numerically rated from 1 (extremely intolerable) to 10 (extremely tolerable). Data after Amendment 3 took effect are excluded.</description>
        <time_frame>Year 1, Year 2, Year 3</time_frame>
        <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Participant-Reported Treatment Satisfaction: How Tolerable or Intolerable Do You Find the Medication?</title>
          <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant’s perception of treatment satisfaction at the end of each year of treatment. For the question &quot;How tolerable or intolerable do you find the medication?&quot; answers were numerically rated from 1 (extremely intolerable) to 10 (extremely tolerable). Data after Amendment 3 took effect are excluded.</description>
          <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1; n=482, 496</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="2.36"/>
                    <measurement group_id="O2" value="7.0" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2; n=425, 430</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="2.28"/>
                    <measurement group_id="O2" value="7.1" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3; n=82, 88</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="2.46"/>
                    <measurement group_id="O2" value="7.3" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Participant-Reported Treatment Satisfaction: How Convenient or Inconvenient Is It to Take Your Medication as Instructed?</title>
        <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant’s perception of treatment satisfaction at the end of each year of treatment. For the question &quot;How convenient or inconvenient is it to take your medication as instructed?&quot; answers were numerically rated from 1 (extremely inconvenient) to 10 (extremely convenient). Data after Amendment 3 took effect are excluded.</description>
        <time_frame>Year 1, Year 2, Year 3</time_frame>
        <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Participant-Reported Treatment Satisfaction: How Convenient or Inconvenient Is It to Take Your Medication as Instructed?</title>
          <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant’s perception of treatment satisfaction at the end of each year of treatment. For the question &quot;How convenient or inconvenient is it to take your medication as instructed?&quot; answers were numerically rated from 1 (extremely inconvenient) to 10 (extremely convenient). Data after Amendment 3 took effect are excluded.</description>
          <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1; n=482, 496</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="2.09"/>
                    <measurement group_id="O2" value="8.0" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2; n=426, 430</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="1.98"/>
                    <measurement group_id="O2" value="8.2" spread="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3; n=82, 88</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="2.05"/>
                    <measurement group_id="O2" value="8.0" spread="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Participant-Reported Treatment Satisfaction: How Convenient or Inconvenient Is It to Take Your Medication Every 2 Weeks?</title>
        <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant’s perception of treatment satisfaction at the end of each year of treatment. For the question &quot;How convenient or inconvenient is it to take your medication every 2 weeks?&quot; answers were numerically rated from 1 (extremely inconvenient) to 10 (extremely convenient). Data after Amendment 3 took effect are excluded.</description>
        <time_frame>Year 1, Year 2, Year 3</time_frame>
        <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Participant-Reported Treatment Satisfaction: How Convenient or Inconvenient Is It to Take Your Medication Every 2 Weeks?</title>
          <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant’s perception of treatment satisfaction at the end of each year of treatment. For the question &quot;How convenient or inconvenient is it to take your medication every 2 weeks?&quot; answers were numerically rated from 1 (extremely inconvenient) to 10 (extremely convenient). Data after Amendment 3 took effect are excluded.</description>
          <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1; n=482, 496</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" spread="2.02"/>
                    <measurement group_id="O2" value="8.4" spread="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2; n=426, 430</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="1.93"/>
                    <measurement group_id="O2" value="8.4" spread="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3; n=82, 88</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="2.00"/>
                    <measurement group_id="O2" value="8.5" spread="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Participant-Reported Treatment Satisfaction: Overall, How Satisfied or Dissatisfied Are You With This Medication?</title>
        <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant’s perception of treatment satisfaction at the end of each year of treatment. For the question &quot;Overall, how satisfied or dissatisfied are you with this medication?&quot; answers were numerically rated from 1 (extremely dissatisfied) to 10 (extremely satisfied). Data after Amendment 3 took effect are excluded.</description>
        <time_frame>Year 1, Year 2, Year 3</time_frame>
        <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Participant-Reported Treatment Satisfaction: Overall, How Satisfied or Dissatisfied Are You With This Medication?</title>
          <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant’s perception of treatment satisfaction at the end of each year of treatment. For the question &quot;Overall, how satisfied or dissatisfied are you with this medication?&quot; answers were numerically rated from 1 (extremely dissatisfied) to 10 (extremely satisfied). Data after Amendment 3 took effect are excluded.</description>
          <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1; n=482, 496</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="2.04"/>
                    <measurement group_id="O2" value="8.1" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2; n=426, 430</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="2.04"/>
                    <measurement group_id="O2" value="8.3" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3; n=82, 88</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="2.00"/>
                    <measurement group_id="O2" value="8.6" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Participant-Reported Treatment Satisfaction: How Satisfied or Dissatisfied Are You With the Injection Frequency (Every 2 Weeks)?</title>
        <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant’s perception of treatment satisfaction at the end of each year of treatment. For the question &quot;How satisfied or dissatisfied are you with the injection frequency (every 2 weeks)?&quot; answers were numerically rated from 1 (extremely dissatisfied) to 10 (extremely satisfied). Data after Amendment 3 took effect are excluded.</description>
        <time_frame>Year 1, Year 2, Year 3</time_frame>
        <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Participant-Reported Treatment Satisfaction: How Satisfied or Dissatisfied Are You With the Injection Frequency (Every 2 Weeks)?</title>
          <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant’s perception of treatment satisfaction at the end of each year of treatment. For the question &quot;How satisfied or dissatisfied are you with the injection frequency (every 2 weeks)?&quot; answers were numerically rated from 1 (extremely dissatisfied) to 10 (extremely satisfied). Data after Amendment 3 took effect are excluded.</description>
          <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1; n=482, 496</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" spread="1.92"/>
                    <measurement group_id="O2" value="8.3" spread="1.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2; n=426, 430</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="1.89"/>
                    <measurement group_id="O2" value="8.3" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3; n=82, 88</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" spread="1.99"/>
                    <measurement group_id="O2" value="8.6" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Participant-Reported Treatment Satisfaction: How Likely Would You Be to Continue to Use This Medication?</title>
        <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant’s perception of treatment satisfaction at the end of each year of treatment. For the question &quot;How likely would you be to continue to use this medication?&quot; answers were numerically rated from 1 (extremely unlikely) to 10 (extremely likely). Data after Amendment 3 took effect are excluded.</description>
        <time_frame>Year 1, Year 2, Year 3</time_frame>
        <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Participant-Reported Treatment Satisfaction: How Likely Would You Be to Continue to Use This Medication?</title>
          <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant’s perception of treatment satisfaction at the end of each year of treatment. For the question &quot;How likely would you be to continue to use this medication?&quot; answers were numerically rated from 1 (extremely unlikely) to 10 (extremely likely). Data after Amendment 3 took effect are excluded.</description>
          <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1; n=482, 496</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="2.11"/>
                    <measurement group_id="O2" value="8.6" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2; n=426, 430</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="2.67"/>
                    <measurement group_id="O2" value="8.3" spread="2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3; n=82, 88</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="2.39"/>
                    <measurement group_id="O2" value="8.8" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Participant-Reported Treatment Satisfaction: This Medication Enables Me to Focus More on Myself and My Family Rather Than My MS.</title>
        <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant’s perception of treatment satisfaction at the end of each year of treatment. For the statement &quot;This Medication Enables Me to Focus More on Myself and My Family Rather Than My MS,&quot; answers were numerically rated from 1 (strongly disagree) to 10 (strongly agree). Data after Amendment 3 took effect are excluded.</description>
        <time_frame>Year 1, Year 2, Year 3</time_frame>
        <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Participant-Reported Treatment Satisfaction: This Medication Enables Me to Focus More on Myself and My Family Rather Than My MS.</title>
          <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant’s perception of treatment satisfaction at the end of each year of treatment. For the statement &quot;This Medication Enables Me to Focus More on Myself and My Family Rather Than My MS,&quot; answers were numerically rated from 1 (strongly disagree) to 10 (strongly agree). Data after Amendment 3 took effect are excluded.</description>
          <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1; n=482, 496</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="2.52"/>
                    <measurement group_id="O2" value="7.8" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2; n=426, 430</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="2.35"/>
                    <measurement group_id="O2" value="7.8" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3; n=82, 88</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="2.44"/>
                    <measurement group_id="O2" value="8.3" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Participant-Reported Treatment Satisfaction: This Medication Makes It Easy For Me to Carry Out My Daily Responsibilities.</title>
        <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant’s perception of treatment satisfaction at the end of each year of treatment. For the statement &quot;This medication makes it easy for me to carry out my daily responsibilities (ie, going to work, doing household chores or caring for my family),&quot; answers were numerically rated from 1 (strongly disagree) to 10 (strongly agree). Data after Amendment 3 took effect are excluded.</description>
        <time_frame>Year 1, Year 2, Year 3</time_frame>
        <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Participant-Reported Treatment Satisfaction: This Medication Makes It Easy For Me to Carry Out My Daily Responsibilities.</title>
          <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant’s perception of treatment satisfaction at the end of each year of treatment. For the statement &quot;This medication makes it easy for me to carry out my daily responsibilities (ie, going to work, doing household chores or caring for my family),&quot; answers were numerically rated from 1 (strongly disagree) to 10 (strongly agree). Data after Amendment 3 took effect are excluded.</description>
          <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1; n=482, 496</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="2.44"/>
                    <measurement group_id="O2" value="7.7" spread="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2; n=426, 429</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="2.32"/>
                    <measurement group_id="O2" value="7.7" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3; n=82, 88</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="2.57"/>
                    <measurement group_id="O2" value="8.3" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Participant-Reported Treatment Satisfaction: The Twice a Month Dosing Makes It More Convenient for Me to Travel/Vacation.</title>
        <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant’s perception of treatment satisfaction at the end of each year of treatment. For the statement &quot;The twice a month dosing makes it more convenient for me to travel/vacation,&quot; answers were numerically rated from 1 (strongly disagree) to 10 (strongly agree). Data after Amendment 3 took effect are excluded.</description>
        <time_frame>Year 1, Year 2, Year 3</time_frame>
        <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Participant-Reported Treatment Satisfaction: The Twice a Month Dosing Makes It More Convenient for Me to Travel/Vacation.</title>
          <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant’s perception of treatment satisfaction at the end of each year of treatment. For the statement &quot;The twice a month dosing makes it more convenient for me to travel/vacation,&quot; answers were numerically rated from 1 (strongly disagree) to 10 (strongly agree). Data after Amendment 3 took effect are excluded.</description>
          <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1; n=482, 496</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="2.21"/>
                    <measurement group_id="O2" value="8.2" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2; n=426, 430</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="2.20"/>
                    <measurement group_id="O2" value="8.2" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3; n=82, 88</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="1.97"/>
                    <measurement group_id="O2" value="8.5" spread="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Participant-Reported Treatment Satisfaction: The Twice a Month Dosing Enables Me to Be More Spontaneous and Flexible.</title>
        <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant’s perception of treatment satisfaction at the end of each year of treatment. For the statement &quot;The twice a month dosing enables me to be more spontaneous and flexible,&quot; answers were numerically rated from 1 (strongly disagree) to 10 (strongly agree). Data after Amendment 3 took effect are excluded.</description>
        <time_frame>Year 1, Year 2, Year 3</time_frame>
        <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Participant-Reported Treatment Satisfaction: The Twice a Month Dosing Enables Me to Be More Spontaneous and Flexible.</title>
          <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant’s perception of treatment satisfaction at the end of each year of treatment. For the statement &quot;The twice a month dosing enables me to be more spontaneous and flexible,&quot; answers were numerically rated from 1 (strongly disagree) to 10 (strongly agree). Data after Amendment 3 took effect are excluded.</description>
          <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1; n=482, 496</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="2.20"/>
                    <measurement group_id="O2" value="8.2" spread="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2; n=426, 430</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="2.12"/>
                    <measurement group_id="O2" value="8.2" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3; n=82, 88</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="2.17"/>
                    <measurement group_id="O2" value="8.4" spread="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Participant-Reported Treatment Satisfaction: This Medication Improves My Self-Confidence and Self-Reliance.</title>
        <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant’s perception of treatment satisfaction at the end of each year of treatment. For the statement &quot;This medication improves my self-confidence and self-reliance,&quot; answers were numerically rated from 1 (strongly disagree) to 10 (strongly agree). Data after Amendment 3 took effect are excluded.</description>
        <time_frame>Year 1, Year 2, Year 3</time_frame>
        <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Participant-Reported Treatment Satisfaction: This Medication Improves My Self-Confidence and Self-Reliance.</title>
          <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant’s perception of treatment satisfaction at the end of each year of treatment. For the statement &quot;This medication improves my self-confidence and self-reliance,&quot; answers were numerically rated from 1 (strongly disagree) to 10 (strongly agree). Data after Amendment 3 took effect are excluded.</description>
          <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1; n=482, 496</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="2.47"/>
                    <measurement group_id="O2" value="7.7" spread="2.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2; n=426, 429</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="2.50"/>
                    <measurement group_id="O2" value="7.9" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3; n=82, 88</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="2.45"/>
                    <measurement group_id="O2" value="8.4" spread="1.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Participant-Reported Treatment Satisfaction: I Am Satisfied With the Dosing Frequency of This Medication.</title>
        <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant’s perception of treatment satisfaction at the end of each year of treatment. For the statement &quot;I am satisfied with the dosing frequency (2 times per month) of this medication&quot; answers were numerically rated from 1 (strongly disagree) to 10 (strongly agree). Data after Amendment 3 took effect are excluded.</description>
        <time_frame>Year 1, Year 2, Year 3</time_frame>
        <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Participant-Reported Treatment Satisfaction: I Am Satisfied With the Dosing Frequency of This Medication.</title>
          <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant’s perception of treatment satisfaction at the end of each year of treatment. For the statement &quot;I am satisfied with the dosing frequency (2 times per month) of this medication&quot; answers were numerically rated from 1 (strongly disagree) to 10 (strongly agree). Data after Amendment 3 took effect are excluded.</description>
          <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1; n=482, 496</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" spread="1.98"/>
                    <measurement group_id="O2" value="8.5" spread="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2; n=425, 430</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" spread="1.83"/>
                    <measurement group_id="O2" value="8.5" spread="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3; n=82, 88</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="1.87"/>
                    <measurement group_id="O2" value="8.7" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Participant-Reported Treatment Satisfaction: Over the Past 4 Weeks, Did You Miss Any of Your Injections?</title>
        <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant’s perception of treatment satisfaction at the end of each year of treatment. For the question &quot;Over the past 4 weeks, did you miss any of your injections?&quot; answer choices were given as &quot;none missed,&quot; &quot;miss 1 injection,&quot; or &quot;miss 2 injections.&quot; Data after Amendment 3 took effect are excluded.</description>
        <time_frame>Year 1, Year 2, Year 3</time_frame>
        <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Participant-Reported Treatment Satisfaction: Over the Past 4 Weeks, Did You Miss Any of Your Injections?</title>
          <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant’s perception of treatment satisfaction at the end of each year of treatment. For the question &quot;Over the past 4 weeks, did you miss any of your injections?&quot; answer choices were given as &quot;none missed,&quot; &quot;miss 1 injection,&quot; or &quot;miss 2 injections.&quot; Data after Amendment 3 took effect are excluded.</description>
          <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment at given timepoint.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1: none missed; n=482, 493</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="474"/>
                    <measurement group_id="O2" value="487"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 1: 1 missed; n=482, 493</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 1: 2 missed; n=482, 493</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2: none missed; n=426, 429</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="422"/>
                    <measurement group_id="O2" value="426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2: 1 missed; n=426, 429</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2: 2 missed; n=426, 429</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3: none missed; n=81, 88</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3: 1 missed; n=81, 88</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3: 2 missed; n=81, 88</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Participant-Reported Treatment Satisfaction: Main Reason for Missed Injections</title>
        <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant’s perception of treatment satisfaction at the end of each year of treatment. For the question &quot;Main reason for missed injections?&quot; answer choices were given as &quot;medication side effects,&quot; &quot;injection pain,&quot; &quot;forget to take medication,&quot; &quot;tired of taking injections,&quot; &quot;don't think medication is working,&quot; or &quot;other.&quot; Data after Amendment 3 took effect are excluded.</description>
        <time_frame>Year 1, Year 2, Year 3</time_frame>
        <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment who missed at least 1 injection at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>BIIB017 Q4W</title>
            <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>BIIB017 Q2W</title>
            <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Participant-Reported Treatment Satisfaction: Main Reason for Missed Injections</title>
          <description>Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant’s perception of treatment satisfaction at the end of each year of treatment. For the question &quot;Main reason for missed injections?&quot; answer choices were given as &quot;medication side effects,&quot; &quot;injection pain,&quot; &quot;forget to take medication,&quot; &quot;tired of taking injections,&quot; &quot;don't think medication is working,&quot; or &quot;other.&quot; Data after Amendment 3 took effect are excluded.</description>
          <population>ITT population: all participants who were assigned a treatment and received at least 1 dose of study treatment; n=participants with an assessment who missed at least 1 injection at given timepoint.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1: medication side effects; n=8, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 1: injection pain; n=8, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 1: forget to take medication; n=8, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 1: tired of taking injections; n=8, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 1: don't think medication is working; n=8, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 1: other; n=8, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2: medication side effects; n=4, 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2: injection pain; n=4, 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2: forget to take medication; n=4, 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2: tired of taking injections; n=4, 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2: don't think medication is working; n=4, 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2: other; n=4, 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3: medication side effects; n=2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3: injection pain; n=2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3: forget to take medication; n=2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3: tired of taking injections; n=2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3: don't think medication is working; n=2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3: other; n=2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 4 years</time_frame>
      <desc>All treatment-emergent events are presented. (An event was considered to be treatment emergent if it had an onset date on or after the date of first study treatment or if it was present prior to start of study treatment and subsequently worsened.)</desc>
      <group_list>
        <group group_id="E1">
          <title>BIIB017 Q4W</title>
          <description>125 µg BIIB017 administered by SC injection Q4W for at least 2 years and up to 4 years.</description>
        </group>
        <group group_id="E2">
          <title>BIIB017 Q2W</title>
          <description>125 µg BIIB017 administered by SC injection Q2W for at least 2 years and up to 4 years.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="114" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Mitral valve prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Basedow's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Heterophoria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Herpes zoster oticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Infectious thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Patellofemoral pain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Endometrial adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Lymphangioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Facial neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Secondary progressive multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Thrombotic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Uhthoff's phenomenon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar 1 disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Catatonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="435" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="438" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="234" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="234" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="222" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="224" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="147" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="132" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="152" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="161" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" subjects_affected="155" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="130" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="529"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Biogen Study Medical Director</name_or_title>
      <organization>Biogen</organization>
      <email>clinicaltrials@biogen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

